Intimation of Press Release regarding the Audited Financial Results for the quarter and financial year ended March 31, 2026.
ANURAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anupam Rasayan India reported strong full-year revenue growth of 65% YoY, reaching Rs 23,836 Mn in FY26 vs Rs 14,485 Mn in FY25. PAT grew 39% to Rs 2,222 Mn. However, Q4FY26 showed a mixed picture with 26% revenue growth but 11% decline in PAT and 6% drop in EBITDA. EBITDA margin compressed significantly from 28% in FY25 to 23% in FY26, and from 30% to 22% on a quarterly basis. The company highlighted landmark achievements including record operating cash flow, successful acquisition of Jayhawk Fine Chemicals in the US (proforma revenue US$95Mn), and signing a definitive agreement to acquire Bliss GVS Pharma to strengthen its pharmaceutical value chain.
While the full year shows robust growth driven by new product commercialization and new customer additions, the margin compression in Q4 and FY26 is a concern. Shareholders should note the improving scale but monitor whether the lower EBITDA margins are a temporary effect of integration costs or a structural shift.